Best SARMs for Female Fat Loss: What the Clinical Evidence Actually Shows

Key takeaways

Regulatory status: no SARM is approved for any use, in any sex

No selective androgen receptor modulator (SARM) has been approved by the FDA or the European Medicines Agency for any medical indication, including fat loss, muscle preservation, or bone protection. A 2024 pharmacology review states plainly that despite years of clinical trials, none has been approved by the Food and Drug Administration (FDA) or European Medicines Agency for pharmacotherapy.

In 2023 the FDA issued a public advisory specifically warning that SARMs, though often marketed as dietary supplements or sold for research use only, are considered unapproved drugs. The agency has tied SARM use to a documented list of adverse events: SARMs have been associated with increased risk of heart attack or stroke, psychosis, sleep disturbances, sexual dysfunction, liver injury/failure, infertility, pregnancy miscarriage and testicular shrinkage.

SARMs are also banned in competitive sport at every level. They are listed in the category of "Other Anabolic Agents" under section S1.2 of the WADA Prohibited List, with named examples including ostarine (enobosarm, MK-2866), andarine, LGD-4033 (ligandrol), and RAD140. All SARMs are prohibited at all times, both in and out of competition, for athletes at any level.

Because no SARM can be legally sold as a supplement or drug in most jurisdictions, products marketed online are unregulated. Consumers most commonly purchase SARMs online, and there is a high risk of these black market products being contaminated with other substances. The FDA and Department of Justice have also pursued criminal cases against sellers, including multi-year prison sentences and multimillion-dollar forfeitures tied to marketing SARMs as dietary supplements.

Why "fat-loss SARM" is a misleading framing to begin with

SARMs were designed as tissue-selective androgen receptor agonists, developed in an attempt to reproduce testosterone's anabolic effects on muscle and bone while limiting androgenic effects elsewhere in the body. The intended pharmacological target was lean mass and bone density, not adipose tissue directly.

Where fat mass changes appear in the clinical literature, they show up as a secondary body-composition finding alongside lean mass gain, generally in trials designed to study muscle wasting, sarcopenia, or cancer cachexia, not as a primary fat-loss endpoint in otherwise healthy women. No published trial has tested any SARM as a cosmetic or performance fat-loss agent in healthy women. Any claim about a "best SARM for female fat loss" is therefore an extrapolation from data collected for a different purpose, in different populations, at different doses than those typically discussed in bodybuilding contexts.

Enobosarm (ostarine): the most studied SARM in women, but not for fat loss

Enobosarm (also known as ostarine, MK-2866, or GTx-024) is the SARM with the largest body of human data that includes women, and it is the compound most often cited in "female-friendly SARM" discussions. That data, however, comes almost entirely from older, postmenopausal, or seriously ill populations under medical supervision, not from healthy women pursuing fat loss.

In a 12-week, double-blind, placebo-controlled phase II trial in healthy elderly men and postmenopausal women, enobosarm produced dose-dependent increases in total lean body mass. No differences in total body weight were observed, indicating that the shift to more lean body composition in the 3-mg-dose group was achieved, at least partially, at the expense of body fat. In numeric terms, the highest (3 mg) dose group saw an average increase in lean body mass of about 1.3 kg alongside roughly a 0.6 kg decrease in fat mass over 12 weeks, alongside a dose-dependent reduction of up to 27% in HDL cholesterol in that same group.

More recently, enobosarm has been tested in combination with the GLP-1 drug semaglutide in adults aged 60 and older with overweight or obesity, aiming to preserve muscle during weight loss rather than to drive fat loss on its own. In that phase 2b trial, enobosarm led to a 27% greater fat mass loss than placebo at 16 weeks, but the reported result did not reach conventional statistical significance (P = .096), and total body weight change was similar between groups. This is a muscle-preservation trial in an older, mixed-sex population on a separate weight-loss drug, not a female-specific fat-loss study.

Enobosarm has also been studied at a fixed 3 mg dose in postmenopausal women with hormone-receptor-positive metastatic breast cancer, where trial authors reported that enobosarm at a dose of 3 mg had no significant virilising side-effects. These findings come from short, tightly monitored oncology trials in postmenopausal women with breast cancer, a very different population and clinical context than young, healthy women seeking cosmetic fat loss.

Despite 25 separate clinical studies and fast-track designation from the FDA, enobosarm has never secured approval for any indication. Its two pivotal phase 3 trials in cancer-related muscle wasting (the POWER trials) failed to meet the co-primary responder endpoints of lean body mass and physical function agreed upon with the FDA, and the drug's sponsor has since pursued other indications, including the ongoing GLP-1 combination studies, without regulatory approval to date.

Other commonly sold SARMs: even less data, and none of it in women for fat loss

Compounds such as LGD-4033 (ligandrol), RAD140, S-4 (andarine), and YK-11 are frequently marketed online as options for women, but controlled human trial data on these compounds is sparse overall and essentially absent in women specifically. A 2023 systematic review of SARM safety in healthy adults identified only 33 total studies (15 case reports/series and 18 clinical trials) across the entire SARM class, with a combined trial population of about 1,447 SARM-exposed subjects, most of them men.

The published case reports of serious harm from these compounds are concentrated in men. Reported cases include a 24-year-old man who had been taking the health supplement RAD-140 for muscle growth for 5 weeks before developing jaundice and liver injury, a 52-year-old man who developed drug-induced liver injury after taking supplements containing RAD-140 and LGD-4033, and a separate case of a 32-year-old man who developed severe drug-induced liver injury after using Ligandrol (LGD-4033). A case report of drug-induced liver injury attributed to enobosarm itself has also been published in the case-report literature.

Because nearly all of the published SARM-related liver injury cases identified involve male users, there is no basis to claim these compounds are safer, or equally risky, in women specifically. The honest statement is that controlled safety data on LGD-4033, RAD140, andarine, or similar compounds in women is essentially absent from the peer-reviewed literature, which is a gap in the evidence, not evidence of safety.

Virilization risk: a real pharmacological concern with a thin evidence base in this specific context

The core biological concern with any androgen receptor agonist in women is virilization, defined in the medical literature as androgen-driven physical changes such as voice deepening, increased muscle bulk, clitoromegaly, and increased body/facial hair. Reviews of SARM pharmacology acknowledge this risk directly: however, androgens can also cause virilization in women, and SARMs' tissue selectivity is relative, not absolute, since some androgenic activity in skin, hair follicles, and other tissues cannot be fully excluded by current compounds.

The reassuring safety data that exists, showing no significant virilising side-effects at a 3 mg enobosarm dose, comes from postmenopausal women in short, closely monitored oncology and body-composition trials at one fixed low dose. It does not establish that ostarine, or any other SARM, is free of virilization risk in premenopausal women, at higher or self-selected doses, over longer durations, or without medical monitoring, all of which differ from how these compounds are typically used outside of clinical trials.

Separately, the broader endocrinology and anabolic-steroid literature is unambiguous that androgen exposure in women can cause virilization that is only partly reversible. In female individuals, anabolic-androgenic steroid misuse can cause virilization, menstrual irregularities, clitoromegaly, and voice deepening, some of which may be irreversible. This body of evidence concerns anabolic-androgenic steroids and pathological androgen excess rather than SARMs specifically. No peer-reviewed case reports of SARM-induced virilization in women were identified in this review, but that reflects how little controlled human SARM research has been done in women outside of select postmenopausal and oncology trials, not a demonstrated absence of risk.

Liver, cardiovascular, and other systemic risks reported across the SARM class

Beyond virilization, the wider SARM literature documents a consistent set of systemic safety signals. A 2023 systematic review found elevated alanine aminotransferase (ALT) was commonly reported in clinical trials in patients exposed to SARMs, with a mean elevation across trials of about 7.1%, along with case reports of drug-induced liver injury, Achilles tendon rupture, and rhabdomyolysis, including two individuals exposed to an investigational SARM (GSK2881078) who developed rhabdomyolysis in a clinical trial.

A separate pharmacology review notes that the FDA has issued a warning letter about the health risks associated with the use of body-building products containing SARMs, citing potential increases in the risk of heart attack or stroke and other life-threatening adverse reactions such as liver damage. These risk signals are drawn from mixed-sex safety data (predominantly male in the case-report literature) and general clinical trial populations, and are not stratified by sex in most published sources, which limits any female-specific risk quantification but does not diminish the risk itself.

Bottom line

There is no clinical trial that identifies a "best" SARM for fat loss in women, and no SARM is approved for human use in general or for fat loss specifically. Enobosarm (ostarine) has the most human data involving women, and some of that data shows fat mass reductions alongside lean mass gains, but the populations studied were postmenopausal or seriously ill and the drug has still never received regulatory approval for any indication after more than two decades of development. Other SARMs commonly marketed to women, such as LGD-4033, RAD140, and andarine, have essentially no controlled trial data in women at all, and the case-report literature on serious harms from these compounds is drawn almost entirely from male users.

Given the unapproved legal status, the documented liver and cardiovascular signals across the class, the near-total absence of controlled safety data in premenopausal women, and the mechanism-based plausibility of virilization risk that has not been ruled out outside of narrow postmenopausal trial contexts, the evidence does not support selecting any SARM for fat loss in women.

Frequently asked

References